PwC MoneyTree is the go-to source for Venture Capital firms and high-growth startups.
The PwC MoneyTree website is home to the PwC/CB Insights quarterly MoneyTree Report. It contains historical trend data (beginning in 1995), updates on the Venture Capital and high-growth startups ecosystem and relevant insights from PwC’s emerging company services and venture capital tax, audit and advisory professionals. The PwC/CB Insights MoneyTree Report is the definitive source of information on venture capital investments in emerging companies. This study is a staple of the financial community, entrepreneurs, government policymakers and the business press worldwide.
For the first quarter of 2019, US venture capital-backed companies saw its first decline in both deals and dollars in a long time. For funding, it was the first material decline since Q3'16 and for deals, it was the third straight quarter decrease. Investors are shifting away from the earliest and riskiest bets with US seed-stage deal share declining to 24% of all deals vs 30% just a year ago. Mega-rounds, which have buoyed funding levels, were also down this quarter although there still is plenty of money for mid- to later-stage companies.
PwC and CB Insights' Healthcare MoneyTree™ report brings you a quarterly publication based on US venture capital funding for healthcare related industries. Each issue is broken out by five key sections: US healthcare trends, US healthcare industries, US healthcare places, US healthcare movers and shakers, and Global healthcare trends.
“Over the past three quarters, we’ve seen the number of deals moderate down, while the total amount invested stays relatively consistent. The prevalence of mega deals — characterized as rounds greater than $100 million — continues to shape the VC landscape.”
Partner, US Pharmaceuticals and Life Sciences , PwC US
Tel: +1 (408) 817 5029